Clinical Efficacy Study · Human Application Test · September 2025

whiteORA
Mela 5D Serum
Efficacy Study

Human application test assessing pigmentation, melanin, skin tone, and uniformity across 8 independently measured endpoints.

23
Subjects
5
Visit Points
4wk
Protocol
0
Adverse Events
8/8
Endpoints Significant
Independent Skin Research Center · Seoul, Korea Chung-Ang University Hospital · Dermatology July 22 – September 1, 2025 23 Subjects · 5 Visits · 4-Week Protocol
41.7%
Reduction in skin surface melanin after 4 weeks

Measured via DermaVision (Red area %). Statistically significant at p<0.0125 (Friedman test, Bonferroni correction). Mean individual improvement rate: 55.3% (median 53.5%). Range: 23.2% to 88.9% — every subject achieved at least 23% reduction. Results statistically maintained 1 week after discontinuation (p=0.322).

23/23 Positive Responders p < 0.0125 Minimum Individual: 23.2% Statistically Maintained Post-Discontinuation
01 —

Study Design

Study Title
A clinical study of WHITEORA MELA 5D SERUM to assess melasma area (density) and prevention of melasma, dark spots, and pigmentation regeneration (maintenance of pigmentation improvement), triple skin tone (yellowness, soothing, brightness) and pigmentation, mottled skin tone (uniformity), deep skin melanin (inner melasma), and skin surface melanin (surface melasma)
Subjects
23 females, ages 40–58 (inclusion criteria: 20–59)
Mean age: 51.70 years
All with existing pigmentation (melasma, dark spots, freckles)
Protocol
4 weeks twice-daily use (AM & PM)
+ 1-week post-discontinuation follow-up
Study: July 22 – September 1, 2025
Application
After cleansing, apply evenly after toner. No other whitening or wrinkle-improvement functional cosmetics permitted during study period.
Statistics
Repeated Measures ANOVA + Bonferroni correction (parametric) · Friedman test + Wilcoxon signed-rank + Bonferroni (non-parametric) · Significance: p<0.05
02 —

Assessment Timeline

Tap a visit node to see what was assessed.

V1
Baseline
Before use
V2
Day 1
After 1st application
V3
Week 2
Mid-point
V4
Week 4
Primary endpoint
V5
+1 Wk Post
After discontinuation
Measurement instruments: Antera 3D CS (melasma area/density) · VISIA-CR → Image-pro® plus (triple skin tone L*a*b*, pigmentation pixel count, skin uniformity, deep melanin) · DermaVision (surface melasma red-area %). Protocol compliance: 99.76% across all 23 subjects (range 96.4–100%). Zero dropouts.
03 —

All 8 Endpoints at a Glance — 4-Week Improvement

Mean % Improvement from Baseline to Week 4 (Cohort, n=23)
Per-subject improvement rates averaged across all 23 subjects. For endpoints where the report uses a group-mean formula, both figures are shown in the metric cards below.
Effect sizes (Cohen's d): Pigmentation 1.84 (very large) · Brightness 0.52 (medium) · Uniformity 0.47 · Surface Melanin 0.39 · Melasma Area 0.33 · Soothing 0.31 · Yellowness 0.19 · Deep Melanin 0.16. All 8 endpoints p<0.05 with Bonferroni correction.
04 —

Primary Efficacy Results — All 8 Metrics

Tap any metric card to expand the trend chart. All improvement rates statistically significant (p<0.05, Bonferroni-corrected). No statistically significant regression observed 1 week after discontinuation on any endpoint.

04b —

Visual Evidence — Best-Case Subject per Endpoint

Clinical imaging data for the highest-performing subject on each of the 8 endpoints. Five assessment timepoints shown side-by-side: Baseline → Day 1 → Week 2 → Week 4 → Post-Discontinuation. Click any image to inspect it full-screen with zoom. Eyes are obscured per standard clinical research protocol.

Skin Surface Melanin
Top Responder · Subject W1-15
−88.9%
Surface Melasma at 4 Weeks
Clinical image — Skin Surface Melanin — Subject W1-15
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
DermaVision thermal mapping. Warm colours indicate active surface melanin. Progressive clearance across all 5 timepoints in the top-performing subject. Cohort mean: −41.7%.
DermaVision · Thermal heat map · Red area %
Pigmentation
Top Responder · Subject W1-04
−37.5%
Pigmented Pixels at 4 Weeks
Clinical image — Pigmentation — Subject W1-04
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
Antera 3D CS: the analysed view (bottom row) marks each pigmented lesion within the measurement circle. Visible reduction in spot density and intensity from Baseline to Week 4.
Antera 3D CS · Original + analysed overlay · Pixel count
Melasma Area Density
Top Responder · Subject W1-04
−29.3%
Melasma-Affected Area at 4 Weeks
Clinical image — Melasma Area Density — Subject W1-04
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
VISIA-CR full-face melanin density map. Warm false-colour tones mark melanin distribution. The progressive lightening from Visit 1 to Visit 4 reflects a 29.3% reduction in affected area.
VISIA-CR → Image-pro® plus · Full-face melanin density map · mm²
Mottled Skin Tone
Top Responder · Subject W1-08
−27.4%
Uniformity at 4 Weeks
Clinical image — Mottled Skin Tone — Subject W1-08
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
Standardised clinical photography under controlled lighting conditions. Reduction in tone irregularity and mottled appearance measured as intensity standard deviation.
VISIA-CR standardised photography · Intensity std
Skin Soothing (a*)
Top Responder · Subject W1-18
−14.2%
Redness Reduction at 4 Weeks
Clinical image — Skin Soothing (a*) — Subject W1-18
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
CIELab photography across 5 timepoints. Reduction in a* (redness axis) indicates a progressively calmer, less inflamed complexion. Significant from Day 1 (p=0.004).
VISIA-CR → CIELab colorimetry · a* redness axis
Skin Yellowness (b*)
Top Responder · Subject W1-22
−12.1%
Yellowness Reduction at 4 Weeks
Clinical image — Skin Yellowness (b*) — Subject W1-22
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
CIELab colorimetry: b* axis. Reduction indicates clearance of the brownish-yellow pigment cast. Visible improvement in skin clarity from Baseline to Week 4 and maintained post-discontinuation.
VISIA-CR → CIELab colorimetry · b* yellowness axis
Skin Brightness (L*)
Top Responder · Subject W1-18
+2.82%
Luminance Increase at 4 Weeks
Clinical image — Skin Brightness (L*) — Subject W1-18
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
Standard clinical photography documenting measurable brightening of skin luminance. The L* axis is the most intuitive metric for patients. Significant improvement from Day 1 (p=0.000).
VISIA-CR → CIELab colorimetry · L* luminance axis
Deep Skin Melanin
Top Responder · Subject W1-21
+10.5%
Inner Melasma at 4 Weeks
Clinical image — Deep Skin Melanin — Subject W1-21
BaselineDay 1Week 2Week 4Post-Disc
Click to inspect
VISIA-CR UV imaging captures dermal melanin deposits. Higher intensity = less melanin absorption = reduction in dermal melanin signal. Measured via UV-mode imaging; statistically significant improvement observed in all 23 subjects (p=0.000, d=0.16).
VISIA-CR UV illumination · Intensity · Inner melasma
Scroll or pinch to zoom · Click & drag to pan
100%
Clinical Efficacy Study · Full Report

Access the Complete Study Report

Get access to the full data, analysed images, key findings summary and much more. Enter your email for an instant access link.

Instant single-use link · Expires in 30 minutes

Check your inbox at .

Access link expires in 30 minutes. Check spam if it doesn't arrive shortly.

Something went wrong. Please try again or reload the page.

Already have access? Open full report →
Also in the full report
05 — Effects After Single Application
06 — Subject Spotlight — Top 3 Responders
07 — Self-Assessment Survey Results
08 — Statistical Appendix & Conclusion